Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare HIV Injectable Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy CS2026D0103W

    Long-Acting Injectable Antiretroviral Agents for HIV

    Customize your policy alerts

    Sign up for UnitedHealthcare Policy CS2026D0103W alerts

    Get alerted when Policy CS2026D0103W changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    UnitedHealthcare Community Plan Medical Benefit Drug Policy governing coverage and prior authorization for Apretude, Cabenuva, Sunlenca, and Yeztugo injections used for HIV prevention or treatment, subject to specified state Medicaid policies or guidelines.

    Policy Summary
    PayerUnitedHealthcare
    PolicyLong-Acting Injectable Antiretroviral Agents for HIV
    Policy CodePolicy CS2026D0103W
    Change TypeAdministrative updateno material clinical or coverage change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization under the medical benefit drug program; initial and continuation authorizations are limited to no more than 12 months when criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Products addressed
    12 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Maximum authorization
    <50 copies/mLCabenuva viral suppression threshold
    ≥35 kgMinimum PrEP weight
    9States outside this policy

    Covered Uses and Exclusions

    Apretude Initial Therapy

    Covered when all of the following are met:

    ALL of the following

    • Apretude initial therapy: Used for HIV-1 pre-exposure prophylaxis (PrEP); the patient has a negative HIV-1 test; the provider confirms HIV-1 testing with each subsequent injection; dosing is in accordance with FDA-approved labeling; and initial authorization is for no more than 12 months.At least 35 kg

      For at-risk adults and adolescents.

    Apretude Continuation Therapy

    Covered when all of the following are met:

    ALL of the following

    • Apretude continuation therapy: The patient has previously received treatment with Apretude; has a negative HIV-1 test; the provider confirms HIV-1 testing with each subsequent injection; dosing is in accordance with FDA-approved labeling; and authorization is for no more than 12 months.At least 35 kg

      Continuation of HIV-1 PrEP.

    Cabenuva Initial Therapy

    Covered when all of the following are met:

    ALL of the following

    • Cabenuva initial therapy

      • Both of the following

        • The patient understands the risks of missed doses of Cabenuva.
        • The patient has the ability to adhere to the required monthly or every 2 months injection appointments.

    Cabenuva Continuation Therapy

    Covered when all of the following are met:

    ALL of the following

    • Cabenuva continuation therapy: The patient has previously received treatment with Cabenuva; the provider confirms that the patient has achieved and maintained viral suppression while on Cabenuva therapy; dosing is in accordance with FDA-approved labeling; and authorization is for no more than 12 months.HIV-1 RNA less than 50 copies per mL

    Sunlenca Initial Therapy

    Covered when all of the following are met:

    ALL of the following

    • Sunlenca initial therapy: The patient has HIV-1 infection with provider-attested multidrug-resistant HIV-1 infection; the patient has been prescribed an optimized background antiretroviral regimen containing at least one antiretroviral agent that demonstrates full viral sensitivity or susceptibility; Sunlenca initial and maintenance dosing is in accordance with FDA-approved labeling; and initial authorization is for no more than 12 months.At least one fully active antiretroviral agent in the optimized background regimen

    Sunlenca Continuation Therapy

    Covered when all of the following are met:

    ALL of the following

    • Sunlenca continuation therapy: The patient has previously received treatment with Sunlenca; the provider confirms a clinically significant viral response to Sunlenca therapy; the patient will continue an optimized background antiretroviral regimen in combination with Sunlenca; Sunlenca maintenance dosing is in accordance with FDA-approved labeling; and authorization is for no more than 12 months.Clinically significant viral response

    Yeztugo Initial Therapy

    Covered when all of the following are met:

    ALL of the following

    • Yeztugo initial therapy: Used for HIV-1 pre-exposure prophylaxis (PrEP); the patient has a negative HIV-1 test; the provider confirms HIV-1 testing with each subsequent injection; dosing is in accordance with FDA-approved labeling; and initial authorization is for no more than 12 months.At least 35 kg

      For at-risk adults and adolescents.

    Yeztugo Continuation Therapy

    Covered when all of the following are met:

    ALL of the following

    • Yeztugo continuation therapy: The patient has previously received treatment with Yeztugo; has a negative HIV-1 test; the provider confirms HIV-1 testing with each subsequent injection; dosing is in accordance with FDA-approved labeling; and authorization is for no more than 12 months.At least 35 kg

      Continuation of HIV-1 PrEP.

    Apretude is excluded for treatment of HIV-1. Under this policy, Apretude is covered for HIV-1 pre-exposure prophylaxis (PrEP) when applicable criteria are met, not as an HIV-1 treatment regimen.

    Cabenuva is excluded for HIV-1 treatment when the patient is not currently virologically suppressed. Virologic suppression is defined as HIV-1 RNA less than 50 copies per mL.

    Sunlenca is excluded for treatment of HIV-1 in patients who are virologically suppressed, for treatment in antiretroviral-naive patients, and for HIV-1 pre-exposure prophylaxis (PrEP).

    Yeztugo is excluded for treatment of HIV-1. Under this policy, Yeztugo is intended for HIV-1 pre-exposure prophylaxis (PrEP) when applicable criteria are met.

    Apretude is unproven and not medically necessary for treatment of HIV-1. Coverage under this policy is for reducing the risk of sexually acquired HIV-1 infection through PrEP in eligible individuals, including those weighing at least 35 kg.

    Cabenuva is unproven and not medically necessary for HIV-1 treatment when the patient is not currently virologically suppressed, defined as HIV-1 RNA less than 50 copies per mL.

    Sunlenca is unproven and not medically necessary for treatment of HIV-1 in virologically suppressed patients, for treatment in antiretroviral-naive patients, or for HIV-1 pre-exposure prophylaxis (PrEP).

    Yeztugo is unproven and not medically necessary for treatment of HIV-1. Under this policy, Yeztugo is covered for HIV-1 pre-exposure prophylaxis (PrEP) when the applicable criteria are met.

    Billing Codes and Clinical Thresholds

    HCPCS CodesHCPCS
    J0738Injection, lenacapavir, 1 mg, FDA-approved prescription, only for use as HIV pre-exposure prophylaxis (not for use as treatment for HIV)
    J0739Injection, cabotegravir, 1 mg, FDA-approved prescription, only for use as HIV pre-exposure prophylaxis (not for use as treatment for HIV)
    J0741Injection, cabotegravir and rilpivirine, 2 mg/3 mg
    J1961Injection, lenacapavir (only for use as HIV treatment), 1 mg
    ICD-10-CM CodesICD-10
    B20Human immunodeficiency virus [HIV] disease
    Z11.3Encounter for screening for infections with a predominantly sexual mode of transmission
    Z11.4Encounter for screening for human immunodeficiency virus [HIV]
    Z16.33Resistance to antiviral drug(s)
    Z20.2Contact with (and suspected exposure to) infections with a predominantly sexual mode of transmission
    Z20.6Contact with (and suspected exposure to) human immunodeficiency virus (HIV)
    Z21Asymptomatic human immunodeficiency virus [HIV] infection status
    Z29.81Encounter for HIV pre-exposure prophylaxis
    Z72.51High risk heterosexual behavior
    Z72.52High risk homosexual behavior
    1–10 of 11
    1/2
    Minimum weight for Apretude and Yeztugo PrEP
    Minimum weightAt least 35 kg
    ProductsApretude and Yeztugo
    PopulationAt-risk adults and adolescents receiving HIV-1 pre-exposure prophylaxis
    Cabenuva viral suppression
    Viral suppression thresholdHIV-1 RNA less than 50 copies per mL
    Initial therapySuppression must be achieved for at least 3 months before Cabenuva initiation
    Continuation therapy

    Authorization and Documentation Requirements

    Prior Authorization

    Obtain authorization for no more than 12 months

    Prior authorization is required under the medical benefit drug program for Apretude, Cabenuva, Sunlenca, and Yeztugo. Initial and continuation authorizations are limited to no more than 12 months when the applicable criteria are met.

    Documentation Required

    Document HIV testing for PrEP

    Before initiating Apretude or Yeztugo, document a negative HIV-1 test. Confirm that HIV-1 testing will occur with each subsequent injection.

    Documentation Required

    Document Cabenuva treatment eligibility

    For Cabenuva, document HIV-1 infection, current stable antiretroviral therapy, and viral suppression with HIV-1 RNA less than 50 copies per mL for at least 3 months before initiation. Also document no prior virologic failures or baseline resistance to cabotegravir or rilpivirine.

    Therapeutic Context

    Apretude and Yeztugo are long-acting injectable options for HIV-1 pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents. PrEP is used to reduce the risk of sexually acquired HIV-1 infection in people without HIV-1 infection; coverage for these products applies to eligible individuals weighing at least 35 kg.

    Policy Terms

    PrEP
    TermPrEP
    DefinitionHIV-1 pre-exposure prophylaxis
    PurposeReduce the risk of sexually acquired HIV-1 infection in people without HIV-1 infection who are at risk
    Virologically suppressed
    TermVirologically suppressed
    DefinitionHIV-1 RNA less than 50 copies per mL
    Cabenuva applicationCabenuva coverage applies to patients who are virologically suppressed on a stable antiretroviral regimen

    Initial Therapy Requirements

    Apretude Initial Therapy

    All of the following are required:

    ALL of the following

    • Apretude initial: Use for HIV-1 PrEP; the patient has a negative HIV-1 test; the provider confirms HIV-1 testing with each subsequent injection; dosing is in accordance with FDA-approved labeling; and initial authorization is for no more than 12 months.At least 35 kg

    Cabenuva Initial Therapy

    All of the following are required:

    ALL of the following

    • Cabenuva initial: The patient has HIV-1 infection; has no prior virologic failures or baseline resistance to cabotegravir or rilpivirine; is currently on a stable antiretroviral regimen; the provider attests that viral suppression has been achieved for at least 3 months before initiation; the patient understands the risks of missed doses; the patient can adhere to required monthly or every 2 months injection appointments; dosing is in accordance with FDA-approved labeling; and initial authorization is for no more than 12 months.

    Continuation Therapy Requirements

    Apretude Continuation Therapy

    All of the following are required:

    ALL of the following

    • Apretude continuation: The patient has previously received treatment with Apretude; has a negative HIV-1 test; the provider confirms HIV-1 testing with each subsequent injection; dosing is in accordance with FDA-approved labeling; and authorization is for no more than 12 months.

    Cabenuva Continuation Therapy

    All of the following are required:

    ALL of the following

    • Cabenuva continuation: The patient has previously received treatment with Cabenuva; the provider confirms that the patient has achieved and maintained viral suppression while on Cabenuva therapy; dosing is in accordance with FDA-approved labeling; and authorization is for no more than 12 months.

    Authorization Duration

    Authorization period
    ProductsApretude, Cabenuva, Sunlenca, and Yeztugo
    Authorization limitNo more than 12 months per authorization period
    RequirementPrior authorization is required under the medical benefit drug program when applicable criteria are met

    Administration Requirements

    Billing Rule

    Administer covered injections in the office

    Sunlenca and Yeztugo injections addressed by this policy are administered by a healthcare professional. Apretude and Cabenuva are injectable products covered under the medical benefit.

    Policy Summary
    PayerUnitedHealthcare
    PolicyLong-Acting Injectable Antiretroviral Agents for HIV
    Policy CodePolicy CS2026D0103W
    Change TypeAdministrative updateno material clinical or coverage change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization under the medical benefit drug program; initial and continuation authorizations are limited to no more than 12 months when criteria are met.
    SourceLink
    On This Page
    Covered Uses and ExclusionsBilling Codes and Clinical ThresholdsAuthorization and Documentation RequirementsTherapeutic ContextPolicy TermsInitial Therapy RequirementsContinuation Therapy RequirementsAuthorization DurationAdministration Requirements
    Viral suppression must be achieved and maintained while on Cabenuva
    Cabenuva pre-initiation suppression duration
    Required durationAt least 3 months
    MeasurementHIV-1 RNA less than 50 copies per mL
    TimingThe patient must achieve viral suppression for this duration before initiating Cabenuva
    Documentation Required

    Document resistance and background therapy

    For Sunlenca, document multidrug-resistant HIV-1 and an optimized background antiretroviral regimen containing at least one antiretroviral agent with full viral sensitivity or susceptibility. For continuation, document a clinically significant viral response and continued use of the optimized background regimen.

    Documentation Required

    Use FDA-label dosing

    Document dosing in accordance with FDA-approved labeling and the applicable initial or maintenance regimen. This requirement applies to Apretude, Cabenuva, Sunlenca, and Yeztugo.

    Denial Risk

    Do not use Apretude for HIV-1 treatment

    Apretude is not medically necessary for treatment of HIV-1 and is covered under this policy for HIV-1 pre-exposure prophylaxis only.

    Denial Risk

    Confirm viral suppression before Cabenuva

    Cabenuva is not medically necessary for HIV-1 treatment when the patient is not currently virologically suppressed. Coverage requires HIV-1 RNA less than 50 copies per mL.

    Denial Risk

    Avoid excluded Sunlenca uses

    Sunlenca is not medically necessary for virologically suppressed HIV-1, HIV-1 in antiretroviral-naive patients, or HIV-1 pre-exposure prophylaxis.

    Denial Risk

    Do not use Yeztugo for HIV-1 treatment

    Yeztugo is not medically necessary for treatment of HIV-1 and is covered under this policy for HIV-1 pre-exposure prophylaxis only.

    Denial Risk

    Confirm HIV-1-negative status before Yeztugo

    Yeztugo is contraindicated when HIV-1 status is unknown or positive because PrEP use in undiagnosed HIV infection carries a risk of drug resistance. Confirm HIV-1 status before treatment.

    Optimized background regimen
    TermOptimized background regimen
    DefinitionA background antiretroviral regimen selected for a patient with resistant HIV-1
    Required componentAt least one fully active antiretroviral agent
    HIV-1 capsid inhibitor
    TermHIV-1 capsid inhibitor
    DrugLenacapavir
    MechanismA multistage, selective inhibitor of HIV-1 capsid function that directly binds between capsid protein p24 subunits in hexamers and interferes with multiple essential steps of the viral lifecycle
    HIV-1 RNA less than 50 copies per mL for at least 3 months before initiation

    Sunlenca Initial Therapy

    All of the following are required:

    ALL of the following

    • Sunlenca initial: The patient has HIV-1 infection with provider-attested multidrug-resistant HIV-1 infection; the patient has been prescribed an optimized background antiretroviral regimen containing at least one antiretroviral agent that demonstrates full viral sensitivity or susceptibility; Sunlenca initial and maintenance dosing is in accordance with FDA-approved labeling; and initial authorization is for no more than 12 months.At least one fully active antiretroviral agent

    Yeztugo Initial Therapy

    All of the following are required:

    ALL of the following

    • Yeztugo initial: Use for HIV-1 PrEP; the patient has a negative HIV-1 test; the provider confirms HIV-1 testing with each subsequent injection; dosing is in accordance with FDA-approved labeling; and initial authorization is for no more than 12 months.At least 35 kg
    HIV-1 RNA less than 50 copies per mL

    Sunlenca Continuation Therapy

    All of the following are required:

    ALL of the following

    • Sunlenca continuation: The patient has previously received treatment with Sunlenca; the provider confirms that the patient has achieved a clinically significant viral response to Sunlenca therapy; the patient will continue an optimized background antiretroviral regimen in combination with Sunlenca; Sunlenca maintenance dosing is in accordance with FDA-approved labeling; and authorization is for no more than 12 months.Clinically significant viral response

    Yeztugo Continuation Therapy

    All of the following are required:

    ALL of the following

    • Yeztugo continuation: The patient has previously received treatment with Yeztugo; has a negative HIV-1 test; the provider confirms HIV-1 testing with each subsequent injection; dosing is in accordance with FDA-approved labeling; and authorization is for no more than 12 months.